Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Sabrina WeberPaul van der LeestHylke C DonkerThomas SchlangeHidde J HaismaMenno TammingaSamantha O PerakisRicarda GrafTina MoserBenjamin SpieglMarie-Laure YaspoLeon W M M TerstappenGrigory A SidorenkovThijo Jeroen N HiltermannMichael R SpeicherEd M D SchuuringEllen HeitzerHarry J M GroenPublished in: JCO precision oncology (2022)
On-treatment changes of ctDNA in plasma reveal predictive information for long-term clinical benefit in ICI-treated patients with NSCLC. A broader NSCLC patient coverage through de novo mutation calling and the use of a variant call set excluding CH-related variants improved the classification of molecular responders, but had no significant impact on survival.
Keyphrases